The predictive marker for detecting T790M from a patient background before treatment in stage4 NSCLC patients harboring EGFR mutaiton (L858R and delition 19): HOPE-002

The predictive marker for detecting T790M from a patient background before treatment in stage4 NSCLC patients harboring EGFR mutaiton (L858R and delition 19): HOPE-002 - The predictive marker for detecting T790M from a patient background before treatment in stage4 NSCLC patients harboring EGFR mutaiton: HOPE-002

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041474

Enrollment

250

Registered

2020-08-21

Start date

2020-08-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: stage4 NSCLC EGFR mutation (L858R or deliton10) positive

Exclusion criteria

Exclusion criteria: recurrent patient

Design outcomes

Primary

Measure	Time frame
Evaluate the predictive marker for detecting T790M from the patient background in stage4 NSCLC patients harbering EGFR mutation	—

Countries

Japan

Contacts

Public ContactMotohiro Tamiya

Osaka International Cancer Institute Thoracic Oncology

moto19781205@yahoo.co.jp06-6945-1181

Outcome results